Status and phase
Conditions
Treatments
About
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
130 participants in 4 patient groups
Loading...
Central trial contact
Verastem Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal